Join to View Full Profile
20 York StNew Haven, CT 06510
Phone+1 203-688-4242
Fax+1 203-688-5013
Dr. Zeidan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Jordan Faculty of MedicineClass of 2001
Rochester Regional Health/Rochester General HospitalResidency, Internal Medicine
Certifications & Licensure
CT State Medical License 2014 - 2027
MD State Medical License 2010 - 2015
NY State Medical License 2007 - 2014
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Clinical Trials
- Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Start of enrollment: 2017 Jun 23
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Start of enrollment: 2019 Jun 26
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
Publications & Presentations
PubMed
- Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.Satoko Ito, Kunal C Potnis, Ding Quan Ng, Kishan K Patel, Manraj Sra
Blood. Red Cells & Iron. 2026-06-01 - Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs.Amer M Zeidan, Sofia Aakko, Maximilian Stahl, Jan P Bewersdorf, Petri Bono
Expert Review of Anticancer Therapy. 2026-05-01 - Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.Mikkael A Sekeres, Valeria Santini, Amer M Zeidan, Uwe Platzbecker, Rami S Komrokji
Blood Neoplasia. 2026-05-01
Lectures
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
Inside Information: Faron to Advance Bexmarilimab into a Registrational Phase 2/3 Study in Treatment-Naïve (Frontline) HR-MDS After Positive Meeting with the FDAAugust 18th, 2025
Is AML Harder to Treat After Relapse?March 6th, 2020
Trovagene (TROV) Stock: Providing New Cancer Treatment Options with OnvansertibDecember 11th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
